{"title":"2019冠状病毒病疫情研究综述","authors":"Yeshwanth Sankranthi, Ittedi Rajashekhar, Ittedi Rani","doi":"10.35248/1948-5948.20.12.449","DOIUrl":null,"url":null,"abstract":"The emergence of SARS-COV2 from Wuhan at the end of December 2019 has spread to 200 countries is the leading cause of deaths. Belonging to be β-COV with single-strand RNA attacks the human respiratory system. The COVID-19 symptoms appear after incubation. The appearance of symptoms varies depending on the age and status of the immune system. Globally, current trials are on vaccines and focused on plasma therapy with the survivor’s plasma.","PeriodicalId":16453,"journal":{"name":"Journal of Microbial & Biochemical Technology","volume":"21 1","pages":"1-7"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Review on Covid-19 Pandemic Outbreak\",\"authors\":\"Yeshwanth Sankranthi, Ittedi Rajashekhar, Ittedi Rani\",\"doi\":\"10.35248/1948-5948.20.12.449\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The emergence of SARS-COV2 from Wuhan at the end of December 2019 has spread to 200 countries is the leading cause of deaths. Belonging to be β-COV with single-strand RNA attacks the human respiratory system. The COVID-19 symptoms appear after incubation. The appearance of symptoms varies depending on the age and status of the immune system. Globally, current trials are on vaccines and focused on plasma therapy with the survivor’s plasma.\",\"PeriodicalId\":16453,\"journal\":{\"name\":\"Journal of Microbial & Biochemical Technology\",\"volume\":\"21 1\",\"pages\":\"1-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Microbial & Biochemical Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/1948-5948.20.12.449\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Microbial & Biochemical Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/1948-5948.20.12.449","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The emergence of SARS-COV2 from Wuhan at the end of December 2019 has spread to 200 countries is the leading cause of deaths. Belonging to be β-COV with single-strand RNA attacks the human respiratory system. The COVID-19 symptoms appear after incubation. The appearance of symptoms varies depending on the age and status of the immune system. Globally, current trials are on vaccines and focused on plasma therapy with the survivor’s plasma.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
